CRISPR system derives specific identification, binding and labelling of target nucleic acid sequences in an in-vitro environment, empowering multiple super-sensitive molecular diagnostic platforms. Taking advantages of this breakthrough technology, CG will develop highly efficient and convenient diagnostic products for liquid biopsy, companion diagnostics and pathogen screening.
Our liquid biopsy platform contains full range of products from cell-free DNA (cfDNA) extraction to circulating tumor DNA (ctDNA) enrichment and quantification, aiming to bringing the mutation detection sensitivity down to 0.01% from blood plasma. The personalized medicine platform focuses on developing nucleic acid fluorescent labelling kit with automatic image analysis and diagnosis system. It simplifies operation procedure and shortens reaction time of traditional fluorescent in-situ hybridization (FISH) with improved signal-to-noise ratio. Furthermore, we also develop highly robust pathogen screening products with single copy number sensitivity. It brings molecular diagnostics, which usually requires a central lab with expensive equipment and tedious nucleic acid handling process, to the field of point-of-care test (POCT).
CRISPR system for advanced molecular diagnostics
|● Highly specific to rare target DNA or RNA with superior detection sensitivity|
|● Capable for pushing nucleic acid detection into the form of POCT|
|● Low cost and scalable platforms for affordable precision diagnostics and personalized medicine|